![dal-PLAQUE study: Hope for CETP inhibition?](/legacy/block/afbeeldingen/dal-PLAQUE-study-Hope-for-CETP-inhibition-006248-220x165px.png) | dal-PLAQUE study: Hope for CETP inhibition? |
| ![Utility of atherosclerosis imaging in the evaluation of drug therapies](/legacy/block/afbeeldingen/Utility-of-atherosclerosis-imaging-in-the-evaluation-of-drug-006249-220x165px.png) | Utility of atherosclerosis imaging in the evaluation of drug therapies |
|
| ![dal-PLAQUE - Background](/legacy/block/afbeeldingen/dal-PLAQUE-Background-006251-220x165px.png) | dal-PLAQUE - Background |
|
![Initial Experience with CETPi](/legacy/block/afbeeldingen/Initial-Experience-with-CETPi-006252-220x165px.png) | Initial Experience with CETPi |
| ![Erik SG Stroes & Diederik F van Wijk Lancet 2011; 378: 1529-1530](/legacy/block/afbeeldingen/Erik-SG-Stroes-Diederik-F-van-Wijk-Lancet-2011-378-1529-1530-006253-220x165px.png) | Erik SG Stroes & Diederik F van Wijk Lancet 2011; 378: 1529-1530 |
|
![Lipid – Efficacy (% change from baseline)](/legacy/block/afbeeldingen/Lipid-%e2%80%93-Efficacy-change-from-baseline-006254-220x165px.png) | Lipid – Efficacy (% change from baseline) |
| ![dal-PLAQUE - Rationale](/legacy/block/afbeeldingen/dal-PLAQUE-Rationale-006255-220x165px.png) | dal-PLAQUE - Rationale |
|
![Why MRI & FDG-PET?](/legacy/block/afbeeldingen/Why-MRI-FDG-PET-006256-220x165px.png) | Why MRI & FDG-PET? |
| ![Measuring atherosclerosis MRI](/legacy/block/afbeeldingen/Measuring-atherosclerosis-MRI-006257-220x165px.png) | Measuring atherosclerosis MRI |
|
![MRI - Logistics](/legacy/block/afbeeldingen/MRI-Logistics-006258-220x165px.png) | MRI - Logistics |
| ![Niacin MRI regression - Oxford study](/legacy/block/afbeeldingen/Niacin-MRI-regression-Oxford-study-006259-220x165px.png) | Niacin MRI regression - Oxford study |
|
![Niacin MRI Regression - Oxford Study](/legacy/block/afbeeldingen/Niacin-MRI-Regression-Oxford-Study-006260-220x165px.png) | Niacin MRI Regression - Oxford Study |
| ![Measuring atherosclerosis PET/CT](/legacy/block/afbeeldingen/Measuring-atherosclerosis-PET-CT-006261-220x165px.png) | Measuring atherosclerosis PET/CT |
|
![FDG-PET/CT scan reproducibility](/legacy/block/afbeeldingen/FDG-PET-CT-scan-reproducibility-006262-220x165px.png) | FDG-PET/CT scan reproducibility |
| ![Evaluating 18F-FDG-PET images of atherosclerosis](/legacy/block/afbeeldingen/Evaluating-18F-FDG-PET-images-of-atherosclerosis-006263-220x165px.png) | Evaluating 18F-FDG-PET images of atherosclerosis |
|
![PET indices derived from the regions of interest (ROI)](/legacy/block/afbeeldingen/PET-indices-derived-from-the-regions-of-interest-ROI-006264-220x165px.png) | PET indices derived from the regions of interest (ROI) |
| ![Attenuation of plaque inflammation by simvastatin by 18FDG PET/CT @ 3 months](/legacy/block/afbeeldingen/Attenuation-of-plaque-inflammation-by-simvastatin-by-18FDG-P-006265-220x165px.png) | Attenuation of plaque inflammation by simvastatin by 18FDG PET/CT @ 3 months |
|
| ![dal-PLAQUE study design and timeline of imaging assessments](/legacy/block/afbeeldingen/dal-PLAQUE-study-design-and-timeline-of-imaging-assessments-006267-220x165px.png) | dal-PLAQUE study design and timeline of imaging assessments |
|
![dal-PLAQUE Sites: Multicenter FDG-PET & MRI Study](/legacy/block/afbeeldingen/dal-PLAQUE-Sites-Multicenter-FDG-PET-MRI-Study-006268-220x165px.png) | dal-PLAQUE Sites: Multicenter FDG-PET & MRI Study |
| ![dal-PLAQUE - Key Inclusion Criteria](/legacy/block/afbeeldingen/dal-PLAQUE-Key-Inclusion-Criteria-006269-220x165px.png) | dal-PLAQUE - Key Inclusion Criteria |
|
![dal-PLAQUE - Predefined Endpoints](/legacy/block/afbeeldingen/dal-PLAQUE-Predefined-Endpoints-006270-220x165px.png) | dal-PLAQUE - Predefined Endpoints |
| ![Baseline characteristics (Intent-to-Treat [ITT]) - Demography and CHD risk factors](/legacy/block/afbeeldingen/Baseline-characteristics-Intent-to-Treat-ITT-Demography-and--006271-220x165px.png) | Baseline characteristics (Intent-to-Treat [ITT]) - Demography and CHD risk factors |
|
![Baseline characteristics (ITT) - Plasma lipid profile](/legacy/block/afbeeldingen/Baseline-characteristics-ITT-Plasma-lipid-profile-006272-220x165px.png) | Baseline characteristics (ITT) - Plasma lipid profile |
| ![Mean change from baseline in plaque burden at 24 Months (MRI) and inflammation at 6 Months (PET/CT)](/legacy/block/afbeeldingen/Mean-change-from-baseline-in-plaque-burden-at-24-Months-MRI--006273-220x165px.png) | Mean change from baseline in plaque burden at 24 Months (MRI) and inflammation at 6 Months (PET/CT) |
|
![Summary of MRI & PET endpoints](/legacy/block/afbeeldingen/Summary-of-MRI-PET-endpoints-006274-220x165px.png) | Summary of MRI & PET endpoints |
| ![Sample MRI Images from a patient at baseline and treated with dalcetrapib 600 mg for 24 Months showing regression in Total Vessel Area (TVA)](/legacy/block/afbeeldingen/Sample-MRI-Images-from-a-patient-at-baseline-and-treated-wit-006275-220x165px.png) | Sample MRI Images from a patient at baseline and treated with dalcetrapib 600 mg for 24 Months showing regression in Total Vessel Area (TVA) |
|
![Raw mean data limited to subjects that provided imaging data for all MRI imaging time points](/legacy/block/afbeeldingen/Raw-mean-data-limited-to-subjects-that-provided-imaging-data-006276-220x165px.png) | Raw mean data limited to subjects that provided imaging data for all MRI imaging time points |
| ![MRI Lumen Area – average carotid (ITT) No change with dalcetrapib vs significant increase with placebo](/legacy/block/afbeeldingen/MRI-Lumen-Area-%e2%80%93-average-carotid-ITT-No-change-with-dalcetra-006277-220x165px.png) | MRI Lumen Area – average carotid (ITT) No change with dalcetrapib vs significant increase with placebo |
|
![Raw mean data limited to subjects that provided imaging data for all PET imaging time points](/legacy/block/afbeeldingen/Raw-mean-data-limited-to-subjects-that-provided-imaging-data-006278-220x165px.png) | Raw mean data limited to subjects that provided imaging data for all PET imaging time points |
| ![Association between HDL-C and arterial inflammation as measured by MDS TBR on PET/CT](/legacy/block/afbeeldingen/Association-between-HDL-C-and-arterial-inflammation-as-measu-006279-220x165px.png) | Association between HDL-C and arterial inflammation as measured by MDS TBR on PET/CT |
|
![Association between atherosclerotic burden (TVA on MRI) and arterial inflammation (MDS TBR on FDG-PET/CT)](/legacy/block/afbeeldingen/Association-between-atherosclerotic-burden-TVA-on-MRI-and-ar-006280-220x165px.png) | Association between atherosclerotic burden (TVA on MRI) and arterial inflammation (MDS TBR on FDG-PET/CT) |
| ![Changes in lipids, lipoproteins, and hs-CRP during the study period](/legacy/block/afbeeldingen/Changes-in-lipids-lipoproteins-and-hs-CRP-during-the-study-p-006281-220x165px.png) | Changes in lipids, lipoproteins, and hs-CRP during the study period |
|
![Inflammatory Markers: Change from Baseline to 24 Months](/legacy/block/afbeeldingen/Inflammatory-Markers-Change-from-Baseline-to-24-Months-006282-220x165px.png) | Inflammatory Markers: Change from Baseline to 24 Months |
| ![Safety variables](/legacy/block/afbeeldingen/Safety-variables-006283-220x165px.png) | Safety variables |
|
![dal-PLAQUE – Overall conclusions](/legacy/block/afbeeldingen/dal-PLAQUE-%e2%80%93-Overall-conclusions-006284-220x165px.png) | dal-PLAQUE – Overall conclusions |
|
Deel deze pagina met collega's en vrienden: